News & Publications – Page 3 – Pittsburgh Pharmacogenomics

2022

2022 | Mar 28

Whole-genome sequencing as an investigational device for return of hereditary disease risk and pharmacogenomic results as part of the All of Us Research Program.

Venner E, Muzny D, Smith JD, Walker K, Neben CL, Lockwood CM, Empey PE, Metcalf GA, Kachulis C, Mian S, Musick A, Rehm HL, Harrison S, Gabriel S, Gibbs RA, Nickerson D, Zhou AY, Doheny K, Ozenberger B, Topper SE, Lennon NJ.

Genome Med. 2022 Mar 28;14(1):34. DOI: 10.1186/s13073-022-01031-z. PMID: 35346344.

2022 | Feb 12

CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention in diverse clinical settings

Beitelshees AL, Thomas CD, Empey PE, Stouffer GA, Angiolillo DJ, Franchi F, Tuteja S, Limdi NA, Lee JC, Duarte JD, Kreutz RP, Skaar TC, Coons JC, Giri J, McDonough CW, Rowland R, Stevenson JM, Thai T, Vesely MR, Wellen JT, Johnson JA, Winterstein AG, Cavallari LH, Lee CR.

J Am Heart Assoc. 2022 Feb 15;11(4):e024159. DOI: 10.1161/JAHA.121.024159. PMID: 35156424.

2021

2021 | Apr 30

A pilot study of oral treprostinil pharmacogenomics and treatment persistence in patients with pulmonary arterial hypertension

Coons JC, Crisamore K, Adams S, Modany A, Simon MA, Zhao W, Shaik IH, Venkataramanan R, Empey PE.

Ther Adv Respir Dis. 2021 Jan-Dec:15:17534666211013688. DOI: 10.1177/17534666211013688. PMID: 33929912.

2021 | Feb 21

Expanding evidence leads to new pharmacogenomics payer coverage

Empey PE, Pratt VM, Hoffman JM, Caudle KE, Klein TE.

Genet Med. 2021 May;23(5):830-832. DOI: 10.1038/s41436-021-01117-w. PMID: 33627827.

2020

2020 | Oct 2

Advanced pharmacy practice experiences in pharmacogenomics offered by US pharmacy programs

Gammal RS, Nguyen J, Audi E, Lee YM, Petry N, Empey PE.

Am J Pharm Educ. 2020 Dec;84(12):ajpe8031. DOI: 10.5688/ajpe8031. PMID: 34283786.

2020 | Oct 2

Impact of the CYP2C19*17 allele on outcomes in patients receiving CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention

Lee CR, Thomas CD, Beitelshees AL, Tuteja S, Empey PE, Lee JC, Limdi NA, Duarte JD, Skaar TC, Chen Y, Cook KJ, Coons JC, Dillon C, Franchi F, Giri J, Gong Y, Kreutz RP, McDonough CW, Stevenson JM, Weck KE, Angiolillo DJ, Johnson JA, Stouffer GA, Cavallari LH.

Clin Pharmacol Ther. 2021 Mar;109(3):705-715. DOI: 10.1002/cpt.2039. PMID: 32897581.

2019

2019 | Aug 15

The “All of Us” research program

All of Us Research Program Investigators.

N Engl J Med. 2019 Aug 15;381(7):668-676. DOI: 10.1056/NEJMsr1809937. PMID: 31412182.

2018

2018 | Jan 30

Multi-site investigation of strategies for the implementation of CYP2C19 genotype-guided antiplatelet therapy

Empey PE, Stevenson JM, Tuteja S, Weitzel KW, Angiolillo DJ, Beitelshees AL, Coons JC, Duarte JD, Franchi F, Jeng LJB, Johnson JA, Kreutz RP, Limdi NA, Maloney KA, Owusu Obeng A, Peterson JF, Petry N, Pratt VM, Rollini F, Scott SA, Skaar TC, Vesely MR, Stouffer GA, Wilke RA, Cavallari LH, Lee CR; for the NHGRI Implementing GeNomics In PracTicE (IGNITE) Network.

Clin Pharmacol Ther. 2018 Oct;104(4):664-674. DOI: 10.1002/cpt.1006. PMID: 29280137.

2016

2016 | Nov 26

PittPharmacy’s Philip Empey is guest editor of special issue of AJHP on precision medicine

Empey PE. Pharmacogenomics to achieve precision medicine.

Am J Health Syst Pharm. 2016 Dec 1;73(23):1906-1907. doi: 10.2146/ajhp160682. PMID: 27784662